New Jersey Requiring Face Masks

Chembio Spikes 8% As Covid-19 Antibody Test Picked For Study

Shares in Chembio Diagnostics (CEMI) spiked 8% on Thursday after the company announced that its DPP Covid-19 point-of-care test has been selected for use by Stony Brook Medicine to recruit coronavirus survivors.Stony Brook is carrying out a study to determine if convalescent blood plasma, the plasma from people who have recovered from Covid-19, can help treat hospitalized patients with active Covid-19 infection.The Chembio test is being used to confirm that patients were infected with Covid-19 and now have adequate levels of IgG antibodies to make them eligible to donate convalescent plasma.The company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes.“We are pleased that our unique and proprietary DPP technology, which can separately and simultaneously detect and measure IgM and IgG antibodies specific to COVID-19, is the assay of choice for Stony Brook Medicine,” stated Javan Esfandiari, Executive VP...